baseline neutrophil counts

Related by string. * baselines . Baselines . BASELINES . BASELINE : Baseline Scenario . sank baseline jumper . baseline jumper . baseline mammogram / neutrophils . Neutrophils . Neutrophil : neutrophil infiltration . neutrophil elastase . non beneficial neutrophil . neutrophil recruitment / counting . counted . Counting : Counter Bulletin Board . Christmas Bird Count . Iraq Body Count * *

Related by context. All words. (Click for frequent words.) 65 log# copies mL 65 stage IIIb IV 65 CD3 + 65 -#.# log# copies mL 64 endometrial thickness 64 8mg/kg 64 cells uL 64 mL/min/#.# m 2 64 severe neutropenia 64 emtricitabine tenofovir 63 infliximab monotherapy 63 μg ml 63 cells μL 63 FUSILEV enhances 63 clodronate 63 mg m² 63 μmol L 63 pCR 63 neutrophil counts 63 achieved ACR# 63 KRAS mutations occur 63 IU ml 63 prostate carcinoma 63 pT3 62 cisplatin resistant 62 ug mL 62 adriamycin 62 mitoxantrone plus 62 tumors GIST 62 PSA nadir 62 μg mL 62 #.#ng/ml 62 autoantibody positive 62 gemcitabine cisplatin 62 median CD4 62 oral clodronate 62 mU liter 62 4mg/kg 62 mitoxantrone chemotherapy 62 PROCTOCORT ® Suppository Hydrocortisone 62 baseline LDH 61 relapsed MM 61 hypermethylated 61 Zometa hazard 61 dasatinib Sprycel ® 61 daunorubicin 61 nM 61 lactate dehydrogenase LDH 61 flutamide 61 metastatic GIST 61 estramustine 61 ABRAXANE therapy 61 SGPT 61 SUVmax 61 biochemical relapse 61 aspartate aminotransferase AST 61 unresectable tumors 61 indinavir 61 cyclophosphamide methotrexate 61 abacavir lamivudine 61 microliter 61 cGy 61 interferon alfa 2a 61 pmol L 61 acid phosphatase PAP 61 hormone receptor negative 61 underwent surgical resection 61 Folfox 61 CD# + [001] 61 advanced adenomas 61 mm Hg diastolic 61 mIU ml 61 HER2 positive tumors 61 placebo dexamethasone 61 5 Fluorouracil 61 oral antidiabetic medication 61 anthracycline taxane 61 lactate dehydrogenase 61 progesterone receptor negative 61 invasive lobular 60 castrate resistant 60 Platinol ® cisplatin 60 alanine aminotransferase 60 metastatic malignant 60 aspartate aminotransferase 60 mm3 60 nanomolar 60 #mmHg [001] 60 umol L 60 baseline CD4 60 hepatocellular carcinomas 60 alanine aminotransferase ALT 60 irinotecan doxorubicin oxaliplatin paclitaxel 60 VELCADE melphalan 60 doxorubicin cyclophosphamide 60 mg qd 60 leukocyte count 60 resistant hormone refractory 60 plus prednisone prednisolone 60 adjuvant cisplatin 60 ovarian carcinoma 60 dexamethasone Decadron 60 Flu Cy 60 mL/min/#.# m2 60 CCyR 60 cells/mm3 60 pg ml 60 HBeAg negative 60 interferon alfa 2b 60 cisplatin chemotherapy 60 % Confidence Interval 60 ErbB2 positive 60 #mg BID [003] 60 PSADT 60 renal cell carcinomas 60 ritonavir boosted 60 substantially excreted 60 nonnucleoside reverse transcriptase inhibitors 60 baseline serum creatinine 60 plus OBT 60 moderate renal impairment 60 HBeAg seroconversion 60 % CI #.#-#.# [003] 60 lymphocytosis 60 Index CDAI score 60 rFSH 60 Peginterferon alfa 2b 59 daily subcutaneous injections 59 uM 59 FOLFOX4 alone 59 myelodysplastic myeloproliferative diseases 59 #ug [002] 59 invasive carcinomas 59 peripheral blood mononuclear 59 Paraplatin ® 59 QTcF 59 Myelosuppression 59 non splenectomized 59 Cream USP 1 59 leucopenia 59 cells mcL 59 extracapsular extension 59 #mg q8h 59 syngeneic 59 PEGylated anti 59 ® lenalidomide 59 Ribavirin causes 59 Endometrial 59 evaluating tivozanib 59 serum prostate 59 neutrophil count 59 locoregional recurrence 59 accumulate preferentially 59 CC genotype 59 antibody titer 59 plasma leptin 59 colorectal carcinoma 59 castration resistant hormone refractory 59 tamoxifen Nolvadex ® 59 mEq L 59 undetectable viral 59 response CCyR 59 paclitaxel cisplatin 59 bioavailable testosterone 59 elevated transaminases 59 ALT elevation 59 alfa 2a 59 EGFR mutation positive 59 nonmetastatic 59 whose tumors overexpress 59 dacarbazine DTIC 59 recurrent metastatic 59 mg kg Hematide 59 #Gy 59 -#.# log# 59 gemcitabine carboplatin 59 mm ³ 59 novel VDA molecule 59 deep venous thromboses 59 ug ml 59 papillary renal cell carcinoma 59 tipranavir r 59 Peg IFN 59 aminotransferases 59 HER2 negative 59 nmol 59 HER2 expression 59 HIV RNA 59 #.#mg/dL 59 μg doses 59 #.#/#.# mmHg [001] 59 lopinavir r arm 59 anti HBs 59 mcg mL 59 mg ustekinumab 59 mGy 59 CYT# potent vascular disrupting 58 ug dose 58 pancreatic prostate 58 completely resected 58 5 FU leucovorin 58 GSTT1 58 nondiabetic patients 58 receiving prophylactic anticoagulation 58 mcg BID 58 mmHg diastolic 58 stage IIIB 58 HER2 amplified 58 serum urate 58 dalteparin 58 log# IU mL 58 protein excretion 58 antiandrogen 58 ng dL 58 Breslow thickness 58 elevated LDH 58 receiving INTRON 58 mmHg systolic 58 -#.# mg dL [001] 58 non mutated KRAS 58 genotype 1b 58 Leukemias 58 #mg/day [002] 58 mmol liter 58 MBq 58 #mg #mg #mg [003] 58 Papillary 58 specific antigen PSA 58 mg TID 58 leukocytosis 58 rizatriptan 58 aplastic anemia AA 58 lopinavir r 58 octreotide LAR 58 Fasting blood glucose 58 GSTP1 58 aminotransferase levels 58 coinfected 58 low dose cytarabine 58 colon carcinoma 58 #ng/ml 58 KRAS mutations 58 triglyceride concentrations 58 leukopenia 58 receiving ISENTRESS 58 CrCl 58 F FLT 58 mm Hg systolic 58 sUA 58 adjunctive placebo 58 mg q#h 58 FOLFIRI alone 58 concentration Cmax 58 lymphocyte count 58 non squamous NSCLC 58 mCi 58 invasive ductal 58 pmol liter 58 IgG antibody 58 -#.# mg dL [002] 58 certolizumab 58 normal karyotype 58 μg L 58 mutated K ras 58 Peginterferon 58 saline placebo 58 Doxil ® 58 lumbar spine BMD 58 FluCAM 58 naïve HCV 58 uL 58 neutropenia dehydration dyspnea 58 recurrent glioblastoma multiforme 58 plus methotrexate 58 CTAP# Capsules 58 micromoles 58 MAGE A3 ASCI 58 Emtriva Viread 58 microg 58 glulisine 58 progression TTP 58 fallopian tube carcinoma 58 nmol liter 58 creatinine ratio 58 atypical hyperplasia 58 Mg Uk 58 ^ F FDG 57 comparator arm 57 surgically resected 57 severe renal impairment 57 lung ovary 57 weekly subcutaneous injections 57 q#h 57 Amgen Neulasta ® 57 Relapsed Refractory 57 serum magnesium 57 lopinavir ritonavir plus 57 histologically confirmed 57 REYATAZ r arm 57 μg dose 57 Ishak fibrosis score 57 Azacitidine 57 advanced adenoma 57 hepatoma 57 3mg/kg 57 prednisone prednisolone 57 B7 H3 57 ertapenem 57 mmol l 57 mg QD 57 chlorambucil 57 sitosterol 57 Immunohistochemical staining 57 highest tertile 57 hormone receptor status 57 mU L 57 KRAS mutant tumors 57 CI -#.# 57 5-FU/LV 57 serum urate levels 57 mcg kg REBETOL 57 nodal metastasis 57 #mg/m# [002] 57 complete cytogenetic response 57 mcg albinterferon alfa 2b 57 HBeAg negative patients 57 x ULN 57 microlitre 57 pyrexia mucositis sepsis febrile 57 CIN3 57 pyrazinamide 57 highly emetogenic 57 confidence interval #.#-#.# 57 renal pelvis 57 p#HER# positive 57 Pharmacokinetics PK 57 pg mL 57 albumin excretion rate 57 Pemetrexed 57 poor metabolizers 57 culture supernatants 57 refractory chronic lymphocytic 57 amprenavir 57 Cutaneous T 57 ribavirin therapy 57 TRAIL induced apoptosis 57 Capecitabine 57 BRAF gene mutations 57 lung carcinomas 57 fasting triglyceride levels 57 glutamic acid decarboxylase 57 binary restenosis 57 KRAS wild 57 bronchoalveolar lavage fluid 57 lowest tertile 57 lispro 57 AUC0 57 g trans fats 57 hours postdose 57 vincristine doxorubicin 57 â ‰ ¥ 57 budesonide pMDI 57 isoprostane 57 5-fluorouracil/leucovorin 57 mIU L 57 dapagliflozin plus 57 Hazard Ratio 57 reduce serum phosphate 57 thyrotropin levels 57 demonstrated antitumor activity 57 nausea dehydration dyspnea 57 HBeAg positive 57 heparanase 57 irinotecan cisplatin 57 radiotherapy RT 57 ovarian pancreatic 57 preoperative chemotherapy 57 operable breast cancer 57 creatinine clearance 56 underwent resection 56 Factor Receptor 56 TPV r 56 sarcomatoid 56 serum calcium levels 56 mCi m 2 56 prednisone prednisolone plus 56 mEq 56 ug kg 56 q8h 56 mg/m2 dose 56 #mg/dL [002] 56 essential thrombocythemia ET 56 nevirapine Viramune 56 achieved CCyR 56 BARACLUDE ® 56 milliliter ng ml 56 TAXUS p value 56 glycated hemoglobin levels 56 CR nPR 56 advanced neoplasia 56 DOXIL 56 EBRT 56 ptau 56 humanized interleukin 6 56 urothelial 56 endometrial ovarian 56 anemia hemoglobin 56 chronic HCV genotype 56 CK # plasma concentrations 56 apolipoprotein B 56 bFGF 56 recurrent NSCLC 56 leukemia AML 56 Usable capacity 56 iPTH 56 bone marrow reticulin deposition 56 #.#-#.# [011] 56 TIMP 56 seroconverted 56 mcL 56 antithymocyte globulin 56 seropositive patients 56 grams dietary fiber 56 TRAIL R1 56 intravenous bolus 56 cisplatin gemcitabine 56 carotid artery intima media 56 intact parathyroid hormone 56 biopsied breast 56 ALT normalization 56 Thal Dex 56 FOLFOX4 56 Serum creatinine 56 aminotransferase elevations greater 56 seminoma 56 Hazard Ratio HR 56 adjunctive ABILIFY 56 tPSA 56 kBq kg 56 histological subtype 56 hyperphenylalaninemia HPA due 56 TT genotype 56 interleukin IL -# 56 colorectal adenocarcinoma 56 % CI #.#-#.# [007] 56 IGF binding 56 minimally symptomatic metastatic castrate 56 pT2 56 lipoprotein Lp 56 Vidaza ® 56 CYP#A# CYP#D# 56 monocyte chemotactic protein 56 binds selectively 56 Adjuvant Treatment 56 urine albumin 56 CK MB 56 tolterodine ER 56 RBC folate 56 pegIFN 56 α tocopherol 56 Apolipoprotein B 56 untreated mice 56 partial remissions 56 Retreatment 56 PENNVAX ™ B 56 prior chemotherapy regimens 56 adjuvant radiation 56 situ LCIS 56 cytokeratin 56 plus dexamethasone 56 fraction LVEF 56 CIN2 56 TAXOTERE R 56 hydroxyvitamin D levels 56 serum HBV DNA 56 normal ULN 56 trastuzumab Herceptin R 56 mCi kg 56 androgen independent 56 hematologic toxicity 56 splenectomized patients 56 tryptase 56 K ras mutations 56 cervical intraepithelial neoplasia 56 transferrin saturation 56 MCyR 56 liver histology 56 undetectable HBV DNA 56 neoadjuvant chemotherapy 56 micrograms mL 56 Forodesine HCl 56 inhibitory concentration 56 g mL 56 investigational oral inhibitor 56 refractory NSCLC 55 undetectable virus HCV 55 HBeAg + 55 abnormal hematopoietic cells 55 epithelial ovarian 55 Bezielle 55 thyroglobulin 55 ASCUS 55 Relapsed Refractory Multiple Myeloma 55 stage IIIB IV 55 mg/m2/day 55 Median PFS 55 nmol l 55 alkylating 55 mso footer margin 55 serum albumin 55 ovarian endometrial 55 EGFR TKI 55 mg simvastatin 55 Median survival 55 serum creatinine levels 55 C#Y 55 peginterferon alpha 2a 55 serum phosphate 55 NovoLog ® Mix 55 PASI scores 55 peginterferon alfa 55 melanoma ovarian 55 Basal Cell 55 Selective Inhibitor 55 #mg dose [002] 55 elevated alkaline phosphatase 55 Plasma concentrations 55 baseline A1C 55 hMG 55 CLINICAL STUDIES 55 APTIVUS r 55 Prognostic significance 55 pheochromocytomas 55 HUMIRA resembles 55 FDG uptake 55 mcg doses 55 -8 -9 55 Perifosine KRX 55 LHRH receptor positive 55 plasma folate 55 ritonavir boosted atazanavir 55 HBsAg positive 55 min -1 55 gram dietary fiber 55 nadir CD4 cell 55 serum potassium 55 nadroparin 55 alanine transaminase 55 systolic diastolic blood 55 Hurthle cell 55 lymphomas leukemias 55 develop premenopausal breast 55 #OHD levels 55 gestational hypertension 55 #mg/kg [002] 55 MIC# [001] 55 serum aminotransferase levels 55 dose cohort 55 castrate resistant prostate cancer 55 CD# CD# 55 HOMA IR 55 Decitabine 55 antiretroviral naïve 55 abnormal p# biomarker 55 Multiple Myeloma MM 55 RRM1 55 epithelial tumors 55 endometrial breast 55 BRCA1 mutation carriers 55 pg g 55 pegylated interferon alfa 2a 55 neoadjuvant 55 transiently transfected 55 plus prednisone 55 serum concentrations 55 estimated glomerular filtration 55 nmol L. 55 autoantibody levels 55 bladder ovarian 55 mg kg dose 55 huN# DM1 55 mcg QD 55 log# reduction 55 detectable HCV RNA 55 HepG2 cells 55 pegylated interferon alpha 55 e antigen HBeAg 55 Ph + acute lymphoblastic 55 hypophosphatemia 55 baseline FEV 55 mucinous 55 humanized therapeutic 55 ® emtricitabine 55 Viread Emtriva 55 seroprotective 55 fructosamine 55 CD4 + cells 55 Pegylated Interferon 55 piperacillin tazobactam 55 Crohn Disease Activity 55 liver metastasis 55 BRAF V#E mutation 55 breast carcinoma 55 SSc 55 Adjuvant chemotherapy 55 lumbar spine bone 55 mutated p# 55 poly ADP ribose polymerase 55 MGd 55 ml min 55 PEG IFN 55 recovery CRp 55 Viral load 55 NRTI backbone 55 triggers apoptosis programmed 55 #.#/#.# mm Hg [003] 55 acetaminophen codeine 55 #mmHg [002] 55 #.#mmHg 55 TOP2A 55 High Dose quadruples 55 mg + GLY 55 #mg/m# [001] 55 circulating endothelial cells 55 epirubicin cyclophosphamide 55 hemagglutination inhibition HAI 55 nontreated 55 del 5q MDS 55 bortezomib refractory 55 cytogenetic responses 55 lymph node metastasis 55 Antigen Specific 55 CIN2 + 55 ATV RTV 55 mg d 55 mg/m2 IV 55 BRAF mutations 55 Hgb 55 T2 lesion volume 55 IFN alfa 55 metaplasia 55 DE Import prc 55 distant metastasis 54 MAGE A3 54 plus aztreonam 54 gastric adenocarcinoma 54 telaprevir dosed 54 CPI yy 54 tertile 54 receiving immunosuppressive therapy 54 thyroid carcinoma 54 golimumab CNTO 54 detemir 54 estim ated fewer 54 erythrocyte sedimentation rate 54 generalized edema 54 tenofovir emtricitabine 54 parous women 54 neoadjuvant therapy 54 hemoglobin A1c HbA1c 54 kaempferol 54 ABCB1 54 mcg kg 54 hemoglobin Hb 54 ischemia driven 54 placebo PBO 54 LDL particle 54 REMICADE monotherapy 54 bladder carcinoma 54 mmol kg 54 #mg BID [001] 54 urine cytology 54 ACR# responses 54 nonfasting triglyceride levels 54 advanced hepatocellular carcinoma 54 log# 54 HGPIN 54 mg calcium 54 BOPD TD 54 unresectable Stage III 54 PREMPRO 54 adjuvant tamoxifen 54 Her2/neu 54 inhibin B 54 anthracycline containing 54 glyburide 54 Response Evaluation Criteria 54 HLA DR 54 #.#in x 54 μg kg 54 UGT#A# * 54 oxycodone IR 54 minimally symptomatic 54 baseline CD4 + 54 #ug [001] 54 epoetin alpha 54 lymphoid blast 54 FIRMAGON 54 elevated ALT 54 Leydig cell 54 HBsAg 54 Clusterin 54 Serum concentrations 54 #mg/dL [001] 54 HBeAg 54 CD8 + lymphocytes 54 DX DEC# 54 Psoriasis Area 54 P ≤ 54 baseline HbA1c 54 absolute neutrophil count 54 rapid virologic response 54 agonistic human 54 mercury mm Hg 54 oxycodone CR 54 thyroid peroxidase 54 glucuronide 54 combination REBETOL PEG 54 mg orally 54 experienced virologic failure 54 preferentially bind 54 dacarbazine 54 nmol L 54 LANTUS R 54 μg d 54 cytidine nucleoside analog 54 TIMP 1 54 decompensated liver disease 54 serum ALT 54 transaminase levels 54 yttrium oxide 54 mU 54 AVODART 54 Cmax 54 subcutaneous enoxaparin 54 ALND 54 CI #.#-#.# [002] 54 #.#mm x [001] 54 metastatic renal cell 54 corticosteroid dose 54 kg -1 54 haematologic 54 systolic blood pressures 54 dehydroepiandrosterone sulfate 54 recurrent VTE 54 preoperative PSA 54 lobular carcinoma 54 multivariable adjusted 54 humanised monoclonal antibody 54 N telopeptide 54 tirofiban 54 beclomethasone dipropionate 54 ERalpha 54 cubic millimeter 54 macrolide antibiotic 54 Regul Integr Comp Physiol 54 AUA BPH Symptom Score 54 HES CEL 54 pooled comparator 54 RECIST Response Evaluation Criteria 54 seropositivity 54 genotypic resistance 54 cytologically confirmed 54 MKC# MT 54 Patients Receiving 54 histologic subtype 54 BCG vaccinated 54 azathioprine 54 seroprotection 54 invasive lobular carcinoma 54 NNRTI resistance 54 μg g 54 breast ovary 54 BRAF V#E 54 ìg 54 anaplastic astrocytomas 54 pegfilgrastim 54 hepatorenal syndrome 54 kg m² 54 medically inoperable 54 LH FSH 54 transaminases 54 % CI #.#-#.# [001] 54 immunohistochemical staining 54 subcutaneous dose 54 RBC transfusions 54 #mg QD [002] 54 baseline Hb 54 distant metastases 54 riffle splitter 54 HIV coinfected 54 Severity MSCS score 54 imatinib therapy 54 Available Seat Kilometres ASKs 54 mRCC 54 hematopoietic cancers 54 biologic DMARD 54 milliliters mL 54 euthyroid 54 recurrent epithelial ovarian 54 % CI #.#-#.# [005] 54 paclitaxel carboplatin 54 mercury mmHg 54 untreated metastatic melanoma 54 dizziness nausea diarrhea 54 DAS# CRP 54 radical prostatectomy RP 54 p# antigen 54 lipid elevations 54 hepatic enzyme 53 debulking surgery 53 HLA DR2 53 fractional shortening 53 receiving VICTRELIS 53 intramuscular dose 53 NMIBC 53 morphometric vertebral fractures 53 LEXIVA r 53 plus COPEGUS 53 + PH# 53 #mg ATC 53 Q2W 53 HbA1C levels 53 LEICA DC VARIO ELMARIT 53 metastatic pancreatic 53 p = .# [002] 53 AZT zidovudine Retrovir 53 LDL cholesterol HDL cholesterol 53 gastrointestinal stromal tumors 53 tumor histology 53 IU mL 53 mycophenolate mofetil 53 prostate cancer mCRPC 53 onset idiopathic hypogonadism 53 lung esophageal 53 OGTT 53 COMBIVIR 53 Apidra ® 53 treatment naïve genotype 53 CD4 + cell 53 #μg [001] 53 serum phosphorus 53 glycosylated hemoglobin HbA1c 53 mg/# hours 53 Upregulation 53 Rectal cancer 53 Ejection Fraction 53 troponin T 53 basal cell carcinoma BCC 53 mg RDEA# 53 #mg/day [001] 53 undergone radical prostatectomy 53 Multipotent 53 systolic dysfunction 53 Adenomas 53 iniparib BSI 53 Solid Tumors RECIST 53 intramuscularly 53 recurrent genital herpes 53 pancreatic adenocarcinoma 53 CCR5 delta# 53 #.#mmol L [002] 53 breast carcinomas 53 idiopathic membranous nephropathy 53 transthyretin TTR 53 MAXIMUM SUSTAINED WINDS ARE 53 squamous cell skin 53 aOR 53 thiazides 53 ejection fractions 53 gastric carcinoma 53 neovasculature 53 aged ≥ 53 ceftriaxone 53 deCODE ProstateCancer TM 53 fluconazole resistant 53 μg liter 53 Telintra 53 methylmalonic acid 53 lamivudine refractory patients 53 osteosarcomas 53 serum PSA 53 mL kg 53 COPEGUS 53 #.#mmol L [001] 53 HbA 1c levels 53 cm ^ sup 53 Lupuzor ™ 53 Phase 2b Clinical Trial 53 GnRH agonist 53 HER2 HER2 53 LV dysfunction 53 mCRPC 53 complete cytogenetic 53 NNT = 53 ZOLINZA 53 miRview squamous 53 folate vitamin B6 53 diastolic hypertension 53 PegIFN 53 posttransplant 53 progesterone receptors 53 HIV uninfected 53 Atypical Hemolytic Uremic Syndrome 53 fasting triglycerides 53 PREPAID WHOLESALE 53 micrometastasis 53 basal cell carcinoma squamous 53 bendamustine ifosfamide 53 diastolic BP 53 annualized relapse 53 TDF FTC 53 mucosal healing 53 breast pancreatic 53 tibolone 53 Pred Forte 53 potent suppressor 53 achieved undetectable HCV 53 nondiabetics 53 GORE TAG Device 53 ERBB2 53 rs# [001] 53 serum HCV RNA 53 Soriatane R acitretin capsules 53 Lenalidomide 53 mcg dose 53 Scale cognitive subscale 53 uterine cervix 53 CR CRu 53 #.#g/day 53 evaluable subjects 53 noncancerous prostate 53 CDKN2A 53 neutropenic patients 53 patients coinfected 53 NPH insulin 53 Hb A1c 53 5 HT2A serotonin 53 #-#-# drlg [004] 53 mso header 53 USP Tablets MOVIPREP ® 53 administered subcutaneously 53 plasma HCV RNA 53 ohm cm 53 limestone xenoliths 53 paraprotein 53 DOXIL ® 53 heavily pretreated 53 amoxicillin clavulanate 53 leiomyoma 53 anti EGFR antibody 53 XIENCE V vs. 53 pulmonary artery pressure 53 Zoledronic acid 53 immunoglobulin G 53 5mm x 6mm x 53 formalin fixed 53 CsA 53 mm DFN package 53 pancreatic carcinoma 53 viral titers 53 biochemical recurrence 53 pulmonary exacerbations 53 hematological cancers notably 53 AGTR1 53 mRNA expression 53 mg eq 53 succinate dehydrogenase 53 WEEK ENDING INDEX 53 anagrelide 53 Aptivus ® 53 hypogonadal 53 milliampere 53 chronic lyme 53 T1a 53 renal cortical 53 Ki# 53 Telik logo TELINTRA 53 PREZISTA ritonavir 53 S. aureus isolates 53 Acute myeloid leukemia 53 statistically significant p = 53 tipranavir ritonavir 53 galiximab 53 low dose Iluvien 53 plus medroxyprogesterone acetate 53 & s2 = 53 Chevrolet Impala #.#L V6 53 cubic milliliter 53 cotrimoxazole 53 osteopenic 53 PTH analogs 53 medullary thyroid 53 x 7mm 53 piotr.skolimowski @ thomson.com 53 mIU mL 53 peak plasma concentrations 53 benazepril 53 cervical lesions

Back to home page